Table 1.
Clinical data
| Healthy controls | Genotype 1 | Genotype 3 | |
|---|---|---|---|
| n | 15 | 22 | 22 |
| Male:Female | 10:5 | 15:7 | 19:3 |
| Caucasian:Asian | 15:0 | 22:0 | 19:3 |
| Age | 44.0 (37.1–50.9) | 45.1 (42.5–47.7) | 40.6 (37.7–43.6) |
| BMI* | 25.2 (23.2–27.1) | 25.4 (24.3–26.6) | 25.1 (23.5–26.7) |
| rs12979860 (CC:CT:TT) | n/d | 5:14:3 | 6:8:2† |
| Previous Treatment Failure (Y:N) | n/a | 11:11 | 4:18 |
| Viral Load (1 × 106 IU/mL)* | n/a | 1.5 (0.7–2.2) | 2.1 (0.6–3.6) |
| FibroScan (kPA) | n/d | 13.7 (6.4–21.1) | 14.6 (7.3–21.9) |
| Serum ALT (IU/mL) | 33.5 (23.6–43.4) | 110.6 (41.6–179.6)‡ | 127.7 (46.0–209.5)‡ |
| Serum Cholesterol (mmol/L) | 5.4 (5.0–5.8) | 5.0 (4.6–5.4) | 3.9 (3.4–4.4)‡§ |
| Serum Total/HDL Cholesterol | 4.6 (3.9–5.2) | 3.8 (3.3–4.3) | 3.9 (3.2–4.6) |
| Haemoglobin (g/L) | 146 (135–157) | 150 (143–156) | 150 (140–159) |
| Platelets (1 × 109/L) | 265 (216–313) | 232 (186–278) | 189 (162–217)‡ |
| White Cell Count (1 × 109/L) | 6.6 (6.0–7.3) | 6.4 (5.6–7.2) | 6.7 (5.8–7.5) |
| Lymphocytes (1 × 109/L) | 2.0 (1.8–2.3) | 2.2 (1.8–2.6) | 2.1 (1.8–2.4) |
| Neutrophils (1 × 109/L) | 3.9 (3.3–4.4) | 3.5 (2.9–4.0) | 3.9 (3.2–4.5) |
All values are given as the mean with the 95% confidence interval in brackets with n/a signifying not applicable and n/d signifying not done.
*
For viral load n = 41 (22 gt1 and 21 gt3); for BMI n = 57 (15 healthy control, 21 gt1 and 21 gt3).
†
Genotype information was unavailable for six gt3-infected patients. Significant differences (P-value<0.05) are denoted as
‡
versus the ‘Healthy Control’ group or
§
versus the ‘Genotype 1’ group.